Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained...

Full description

Saved in:
Bibliographic Details
Published in:Ann Rheum Dis
Main Authors: Landewé, Robert BM, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip E, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, Davies, Owen R, de Peyrecave, Natasha, Thomas, Karen, Gensler, Lianne
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Spondyloarthritis
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://ncbi.nlm.nih.gov/pubmed/32381562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216839
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items